PL3202772T3 - Kryształ kompleksu inhibitora l-proliny/glukozy sodowej 2 - Google Patents

Kryształ kompleksu inhibitora l-proliny/glukozy sodowej 2

Info

Publication number
PL3202772T3
PL3202772T3 PL15846001.4T PL15846001T PL3202772T3 PL 3202772 T3 PL3202772 T3 PL 3202772T3 PL 15846001 T PL15846001 T PL 15846001T PL 3202772 T3 PL3202772 T3 PL 3202772T3
Authority
PL
Poland
Prior art keywords
proline
inhibitor
sodium
crystal
complex
Prior art date
Application number
PL15846001.4T
Other languages
English (en)
Inventor
Piaoyang Sun
Guaili Wu
Changshan GUO
Yun Lu
Yuxia Wu
Lingjia SHEN
Original Assignee
Jiangsu Hengrui Medicine Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co. Ltd. filed Critical Jiangsu Hengrui Medicine Co. Ltd.
Publication of PL3202772T3 publication Critical patent/PL3202772T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL15846001.4T 2014-09-30 2015-09-08 Kryształ kompleksu inhibitora l-proliny/glukozy sodowej 2 PL3202772T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410523436 2014-09-30
PCT/CN2015/089128 WO2016050134A1 (zh) 2014-09-30 2015-09-08 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体

Publications (1)

Publication Number Publication Date
PL3202772T3 true PL3202772T3 (pl) 2021-02-22

Family

ID=55629417

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15846001.4T PL3202772T3 (pl) 2014-09-30 2015-09-08 Kryształ kompleksu inhibitora l-proliny/glukozy sodowej 2

Country Status (13)

Country Link
US (1) US10301344B2 (pl)
EP (1) EP3202772B1 (pl)
JP (1) JP6761564B2 (pl)
KR (1) KR20170060035A (pl)
CN (1) CN105992769B (pl)
BR (1) BR112017005454A2 (pl)
CA (1) CA2961819C (pl)
ES (1) ES2836099T3 (pl)
HU (1) HUE052588T2 (pl)
PL (1) PL3202772T3 (pl)
PT (1) PT3202772T (pl)
TW (1) TWI680983B (pl)
WO (1) WO2016050134A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512910A (ja) * 2018-02-07 2021-05-20 リアタ ファーマシューティカルズ インコーポレイテッド ノボビオシン類似体とプロリンとの共結晶形態
CN112375087A (zh) * 2020-11-27 2021-02-19 浙江天宇药业股份有限公司 一种脯氨酸恒格列净的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011002166A (es) * 2008-08-28 2011-04-07 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol.
ES2544272T3 (es) * 2010-03-17 2015-08-28 Katholieke Universiteit Leuven Almacenamiento de productos que respiran
CN102372722A (zh) 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用
KR20150048720A (ko) * 2012-07-11 2015-05-07 오시리스 쎄라퓨틱스, 인크. 연골 제품 제조 방법
US9145434B2 (en) * 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
EP4245765A3 (en) * 2013-04-04 2024-03-20 Boehringer Ingelheim Vetmedica GmbH Treatment of metabolic disorders in equine animals
CN104031098A (zh) * 2014-06-21 2014-09-10 李友香 降糖药物
CN104017031A (zh) 2014-06-21 2014-09-03 李友香 降血糖药物和组合物

Also Published As

Publication number Publication date
CA2961819A1 (en) 2016-04-07
TW201612188A (en) 2016-04-01
EP3202772A4 (en) 2017-08-09
TWI680983B (zh) 2020-01-01
BR112017005454A2 (pt) 2017-12-12
HUE052588T2 (hu) 2021-05-28
CA2961819C (en) 2022-11-08
US20170298087A1 (en) 2017-10-19
WO2016050134A1 (zh) 2016-04-07
ES2836099T3 (es) 2021-06-24
PT3202772T (pt) 2020-11-20
US10301344B2 (en) 2019-05-28
JP6761564B2 (ja) 2020-09-30
CN105992769B (zh) 2019-04-02
EP3202772A1 (en) 2017-08-09
KR20170060035A (ko) 2017-05-31
EP3202772B1 (en) 2020-10-28
CN105992769A (zh) 2016-10-05
JP2017530107A (ja) 2017-10-12

Similar Documents

Publication Publication Date Title
IL277299B (en) Cyclopropylamines as lsd1 inhibitors
IL277167B (en) Cyclopropylamines as lsd1 inhibitors
ZA202007274B (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
IL249345A0 (en) Disubstituted indazole compounds used as irak4 inhibitors
IL250642B (en) glycosidase inhibitors
IL246555A0 (en) Indazole compounds as irak4 inhibitors
GB2526275B (en) Display for reducing speckle
AP2016009297A0 (en) Novel heterocyclic compounds
AU356457S (en) Wrist watch
GB201608586D0 (en) Improvements to open display refridgerators
GB201403536D0 (en) Inhibitor compounds
ZA201808552B (en) Novel b-lactamase inhibitors
PL3174849T3 (pl) Synteza pochodnych pirolidyny
HUE052588T2 (hu) Az L-prolin/nátrium-glukóz kotranszporter 2 gátló kristály komplexének kristálya
PT3395819T (pt) Forma cristalina de derivado de aminopirano substituído
GB201401005D0 (en) Inhibitor
EP3256481A4 (en) Novel crystalline form of a proteasome inhibitor
GB201411737D0 (en) Holographic display
PH32014000713S1 (en) Watch hands
AU363038S (en) Decorative plate for jewellery
AU2014900982A0 (en) Jewellery Box
GB201402719D0 (en) Clocks/watches No 2